Company intelligence / Profile preview

LiquidLung

Newport Beach, California, United States

Ownership: Private
Development stage: Other

Overview

LiquidLung has developed a blood-based multi-RNA biomarker liquid biopsy platform for lung cancer that, in independent validation, achieved about 97% sensitivity and 79–85% specificity for lung cancer detection, including 100% detection of stage I, III and IV and ~89% of stage II cases, and can distinguish major lung cancer histologic subtypes[1][2][3][4][5].

Therapeutic areas: OncologyPulmonology
Modalities: Diagnostic assayRNA therapyLiquid biopsy
Industry: Molecular Diagnostics

Partnerships

P4 Diagnostix (strategic laboratory partnership to scale clinical development and commercialization of IV BioHoldings’ lung cancer diagnostics, including LiquidLung)[1][2][3].Liquid Biosciences (bio-analytics partner providing the Emerge bio-analytics platform for biomarker discovery and modeling)[1][2][3].

Beyond the preview

Go deeper on LiquidLung.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LiquidLung.

Explore the full profile